Correlation between Androgen Receptor Expression and Immunohistochemistry Type as Prognostic Factors in a Cohort of Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study
Open Access
- 3 March 2021
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 9 (3), 277
- https://doi.org/10.3390/healthcare9030277
Abstract
Background: We investigated the correlation between the androgen receptor (AR) and immunohistochemistry (IHC) as a prognostic factor in breast cancer (BC). AR is expressed in 60–80% of BC. Methods: We evaluated the prognostic values of AR expression among 143 patients with BC for 36 months. The protocol was amended to measure androgen, estrogen and progesterone receptor expression by IHC and the percentage of hormone positive nuclei was quantified. We determined and quantified the Her2/neu status using IHC and in situ hybridization. The methodology consisted in using a Kaplan–Meier analysis and restricted mean survival time up to 36 months. The principal endpoints of the study were overall survival (OS) and progression free survival (PFS). Results: 57% of patients (n = 82) from our group had AR+ (≥ 1%). Patients with AR+ had better OS, 35.50 vs. 33.40 months, with p = 0.027. Moreover, PFS was prolonged for patients AR+, 32.60 vs. 30.50 months, with p = 0.38. Triple negative breast cancer (TNBC) patients had lower OS and no difference was observed for PFS. Conclusions: Both OS and PFS were favorably influenced by the presence of AR. TNBC had worse outcomes compared with patients with hormonal or/and Her 2/neu positive disease in terms of OS.This publication has 55 references indexed in Scilit:
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health StudyLaboratory Investigation, 2011
- Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal WomenClinical Cancer Research, 2011
- Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancersAnnals of Oncology, 2011
- Risk of mortality in patients with cancer who experience febrile neutropeniaCancer, 2010
- Conjugated and non-conjugated androgens differentially modulate specific early gene transcription in breast cancer in a cell-specific mannerSteroids, 2010
- Activated Androgen Receptor Downregulates E-Cadherin Gene Expression and Promotes Tumor MetastasisMolecular and Cellular Biology, 2008
- Androgen receptors frequently are expressed in breast carcinomasCancer, 2003
- Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators on Node-Negative Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 1993
- Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitorsCritical Reviews in Oncology/Hematology, 1986